Rhodah Simiyu
Psychiatric/Mental Health · Albuquerque, NMNPI 1942981543
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 122 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 25.3% of the total. 2025 is the largest year on record at $2,434, more than ten times the $33 reported in 2023. Among psychiatric/mental health clinicians in NM with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 122 payments — averaging $32.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$579
- Johnson & Johnson$479
- AbbVie$393
- Teva Pharmaceuticals USA, Inc.$323
- Otsuka America Pharmaceutical, Inc.$306
- plus $892 from 9 others
What the payments were for
- Food & beverage$3,979100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 27 | $1,008 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 17 | $579 |
| Johnson & Johnson | 14 | $479 |
| AbbVie | 10 | $393 |
| Teva Pharmaceuticals USA, Inc. | 20 | $323 |
| Otsuka America Pharmaceutical, Inc. | 9 | $306 |
| Vanda Pharmaceuticals Inc. | 5 | $204 |
| E.r. Squibb & Sons, L.L.C. | 4 | $193 |
| Janssen Scientific Affairs, LLC | 1 | $138 |
| Alkermes, Inc. | 5 | $127 |
| Lundbeck LLC | 3 | $91 |
| Axsome Therapeutics, Inc. | 3 | $57 |
| OWP Pharmaceuticals, Inc. | 2 | $39 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| Tris Pharma Inc | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,979 in reported general payments places this provider in the 90th percentile of 228 psychiatric/mental health providers in New Mexico.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Duloxetine Hcl | 19 | $1,038 |
| Buspirone Hcl | 44 | $651 |
| Quetiapine Fumarate | 44 | $542 |
| Hydroxyzine Hcl | 21 | $513 |
| Doxepin Hcl | 19 | $358 |
| Trazodone Hcl | 38 | $288 |
| Olanzapine | 17 | $262 |
| Sertraline Hcl | 36 | $252 |
| Divalproex Sodium | 12 | $242 |
| Gabapentin | 13 | $216 |
| Lamotrigine | 18 | $205 |
| Topiramate | 12 | $188 |
| Mirtazapine | 24 | $125 |
| Alprazolam | 30 | $119 |
| Lorazepam | 16 | $90 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Albuquerque
- Martha SnowAlbuquerque$13K
- Tiny AdamsAlbuquerque$6K
- Melissa LeuzziAlbuquerque$4K
- Petra Lamla LabanAlbuquerque$3K
- Jennifer ClysdaleAlbuquerque$3K
- Diane ElmanAlbuquerque$2K
- Bryan KrummAlbuquerque$2K
- Charlotte NkwentiAlbuquerque$2K
- Desiree ProvencioAlbuquerque$2K
- Denis MuebakeAlbuquerque$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.